News · Fitness & Exercise
Exercise improved arteries where liraglutide did not
A Nature Metabolism analysis of 130 adults keeping weight off found exercise thinned artery walls and cut inflammation, while the drug liraglutide alone did neither despite similar weight control.
- 130 adults who had lost weight, randomized to keep it off with exercise, liraglutide, both or neither.
- Exercise thinned artery walls, a measure that tracks with cardiovascular risk.
- It also lowered the inflammatory signals interleukin-6 and interferon-gamma.
- Liraglutide alone did neither, despite being an effective weight-maintenance drug.
- Surrogate markers over a year, not heart attacks, and liraglutide is an older GLP-1 drug.
If a drug and a treadmill keep the same weight off, does it matter which you use? A trial analysis in Nature Metabolism suggests the arteries can tell the difference.
Following 130 adults through a year of weight maintenance, researchers found that exercise, alone or in combination with liraglutide, reduces carotid intima-media thickness and systemic pro-inflammatory cytokine levels. Liraglutide alone shows no such improvements.
Why exercise versus liraglutide is newly urgent
Weight-loss drugs work, and the debate has moved on to what they do not do. Muscle loss is one open front. Vascular health is another, and it matters because the point of losing weight is usually the heart.
The premise the researchers start from is standard: obesity and inactivity are linked to endothelial dysfunction and atherosclerosis. Endothelial dysfunction means the single-cell lining of blood vessels stops regulating blood flow properly, and it is one of the earliest measurable steps toward heart disease.
Until now these two routes to weight maintenance had rarely been compared on that specific outcome.
An unusual trial design
The parent study did something more realistic than most. In this secondary analysis of the S-LiTE trial, 130 adults with obesity completed a diet-induced weight loss plan, followed by randomization to weight maintenance with exercise and/or liraglutide for 52 weeks.
Everyone lost the weight the same way first. The randomization decided only how they held onto it, across four arms: exercise, drug, both, or neither.
That structure isolates the maintenance strategy, which is where most weight-loss efforts actually fail.
What exercise did to artery walls
Exercise moved the vascular markers. Exercise, alone or in combination with liraglutide, reduces carotid intima-media thickness and systemic pro-inflammatory cytokine levels, specifically interleukin-6 and interferon-gamma.
The combination did more still. Combination treatment also improves endothelial function biomarkers, covering three separate measures of how well the vessel lining is behaving.
And the drug on its own did not. Liraglutide alone shows no such improvements.
Why liraglutide may have fallen short
The obvious inference is that exercise does something to blood vessels that weight loss by itself does not. Both arms maintained their weight loss; only the exercising arms improved.
Mechanically that is plausible. Exercise repeatedly increases blood flow across the vessel lining, and that mechanical stress is a known stimulus for endothelial health. The drop in inflammatory signaling the researchers measured offers a second route.
But this is a secondary analysis of 130 people, reporting surrogate markers rather than clinical events. Artery wall thickness predicts heart attacks; it is not one. A year is short for vascular remodelling, and the trial was not powered to detect differences in outcomes that matter to patients.
The drug also deserves fair treatment. Liraglutide is an older, weaker GLP-1 agent than what is prescribed today, and the larger cardiovascular outcome trials in this class have shown real event reduction in people with established heart disease. This analysis says liraglutide did not improve these markers here, not that GLP-1 drugs fail the heart.
What the artery findings cannot show
The authors’ summary is unusually direct for a secondary analysis: regular physical activity, with or without GLP-1 receptor agonists, is essential for promoting vascular health in adults with obesity.
Which is the practical point. The drugs are being framed as an alternative to exercise, and on the scale they may be. On the arteries, at least in this trial, they were not a substitute.
People also ask
Does this mean weight-loss drugs are bad for your arteries?
No. It means liraglutide alone did not improve these particular vascular markers over a year, while exercise did. That is an absence of benefit on specific measures, not evidence of harm. Separate large trials have shown cardiovascular benefit for GLP-1 drugs in people with existing heart disease, measured as actual events rather than markers.
What is carotid intima-media thickness?
It is the combined thickness of the two inner layers of the carotid artery wall in the neck, measured by ultrasound. It thickens with age and with atherosclerosis, and greater thickness tracks with higher cardiovascular risk. It is a surrogate marker: useful, non-invasive and quick to change, but not the same as a heart attack.
Both groups kept the weight off, so why the difference?
That is what makes the result interesting. If the vascular benefit came purely from being lighter, both arms should have improved. Instead the benefit tracked with exercise specifically, which points to something exercise does beyond weight, such as shear stress on vessel walls, improved endothelial signaling, or the lower inflammation the study also measured.
Would newer drugs like semaglutide do better?
Unknown from this trial, which tested liraglutide, a daily and less potent GLP-1 drug than the current generation. Newer agents produce more weight loss and have their own cardiovascular outcome data. Whether they would match exercise on artery wall thickness has not been tested this way, so nothing here should be extrapolated to them.
How much exercise was involved?
The trial's exercise arm followed a supervised program over the 52-week maintenance period, alongside the diet-induced weight loss everyone completed first. This secondary analysis reports the vascular results rather than the prescription. The practical message is about exercise being retained during weight maintenance, not about a specific workout.